

The FDA's landmark decision to approve Aduhelm leaves payers with an incredible challenge – that is, how to provide affordable access to appropriate patients.

If the results of our LinkedIn Survey are any indication, restrictions are likely.

With the FDA's approval of Aduhelm, how do you think payers are most likely to respond?

